Cruelty Free International welcomes major shift towards humane, modern approaches to drug development and testing ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

The U.S. Food and Drug Administration (FDA) has announced an ambitious effort to modernize drug testing by reducing reliance ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Recuresion Pharma (RXRX) stock and other AI-driven biotechs surge as FDA embraces computational models over animal testing ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

The FDA announced a shift away from animal testing for drug approval, citing advanced alternatives like AI and organoids ...